Great Point Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Great Point Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.6M	Sell	675,000 -10,632	-2%	-$171K	3.12%	11
2025 Q4	$11.1M	Buy	+685,632	New	+$9.08M	3.59%	11
2025 Q3	–	Sell	-323,170	Closed	-$3.65M	–	35
2025 Q2	$3.65M	Sell	323,170 -691,197	-68%	-$8.45M	2.38%	16
2025 Q1	$11.7M	Sell	1,014,367 -772,636	-43%	-$7.89M	6.2%	2
2024 Q4	$15.1M	Buy	1,787,003 +487,500	+38%	+$5.05M	7.13%	3
2024 Q3	$15M	Sell	1,299,503 -39,065	-3%	-$491K	4.43%	7
2024 Q2	$15.8M	Buy	+1,338,568	New	+$15.6M	3.02%	13
2023 Q2	–	Sell	-1,600,545	Closed	-$12.6M	–	46
2023 Q1	$12.6M	Buy	1,600,545 +544,744	+52%	+$4.06M	2.47%	19
2022 Q4	$7.14M	Sell	1,055,801 -495,918	-32%	-$2.66M	1.4%	25
2022 Q3	$22.5M	Buy	1,551,719 +21,719	+1%	+$304K	5.42%	7
2022 Q2	$15.1M	Buy	1,530,000 +655,803	+75%	+$7.23M	3.61%	11
2022 Q1	$12.9M	Buy	874,197 +462,260	+112%	+$6.64M	3.11%	15
2021 Q4	$5.45M	Buy	+411,937	New	+$6.56M	1.21%	28

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Great Point Partners's KALV Position: Q1 2026 in Review

Great Point Partners reduced its KalVista Pharmaceuticals (KALV) stake by 1.6% in Q1 2026, selling an estimated $171K and leaving 675,000 shares worth $13.6M. The position accounts for 3.12% of the portfolio, ranked #11.

Great Point Partners first reported a position in KALV in Q4 2021 and has held it in 13 quarters since. The position peaked at $22.5M in Q3 2022. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Great Point Partners held 675,000 shares of KalVista Pharmaceuticals worth $13.6M as of Q1 2026.
Great Point Partners sold 10,632 KalVista Pharmaceuticals shares in Q1 2026, an estimated $171K.
KalVista Pharmaceuticals made up 3.12% of Great Point Partners's portfolio in Q1 2026, its #11 holding.
Great Point Partners first reported a position in KalVista Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
Great Point Partners's KalVista Pharmaceuticals position peaked at $22.5M in Q3 2022.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.